Name: Sonoma Pharmaceuticals, Inc. (SNOA) Financial Statements
Creator: FinSpry

Sonoma Pharmaceuticals Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scale:

Scroll to see more

Sonoma Pharmaceuticals, Inc. income statement - Annual data in millions USD
Breakdown	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Dec 2025	Mar 2024	Mar 2023	Mar 2022	Mar 2021
Revenue & Gross Profit
Revenue	14.29	12.74	13.27	12.63	18.63
Cost of Revenue	8.82	7.99	8.80	8.64	12.07
Gross Profit	5.47	4.75	4.48	3.99	6.56
Operating Expenses
Research & Development	1.81	1.87	0.21	0.13	0.56
Selling, General & Administrative	7.36	7.58	8.84	9.76	9.45
Operating Expenses	9.18	9.45	9.05	9.88	10.01
Operating Income	-3.71	-4.70	-4.57	-5.89	-3.45
Other Income/Expense
Interest Income	0.00	0.00	0.00	0.00	0.00
Interest Expense	0.00	0.00	0.00	-0.01	0.00
Other Income/Expense	0.80	0.50	-0.63	0.48	0.10
Income
Income Before Tax	-2.91	-5.03	-5.18	-5.42	-3.90
Income Tax Expense	0.55	-0.20	-0.03	-0.33	0.71
Net Income	-3.46	-4.84	-5.15	-5.09	-3.95
Net Income - Continuous Operations	-3.46	-4.84	-5.15	-5.09	0.00
Net Income - Discontinued Operations	0.00	0.00	0.00	0.00	0.00
EBITDA	-3.57	-4.53	-5.06	-5.70	-3.22
EBIT	-3.71	-4.70	-5.18	-5.89	-3.45
Depreciation & Amortization	0.14	0.18	0.13	0.19	0.23
Earnings Per Share
Basic EPS	-3.00	-11.00	-30.00	-38.00	-40.00
Diluted EPS	-3.00	-11.00	-30.00	-38.00	-40.00
Basic Shares Outstanding	1.24	0.46	0.00	0.13	0.10
Diluted Shares Outstanding	1.24	0.46	0.00	0.13	0.10